Wound healing is a hierarchical process of intracellular and intercellular signaling. Insulin is a potent chemoattractant and mitogen for cells involved in wound healing. Insulin's potential to promote keratinocyte growth and stimulate collagen synthesis in fibroblasts is well described. However, there currently lacks an appropriate delivery mechanism capable of consistently supplying a wound environment with insulin; current approaches require repeated applications of insulin, which increase the chances of infecting the wound. In this study, we present a novel cell-based therapy that delivers insulin to the wound area in a constant or glucose-dependent manner by encapsulating insulin-secreting cells in nonimmunogenic poly(ethylene glycol) diacrylate (PEGDA) hydrogel microspheres. We evaluated cell viability and insulin secretory characteristics of microencapsulated cells. Glucose stimulation studies verified free diffusion of glucose and insulin through the microspheres, while no statistical difference in insulin secretion was observed between cells in microspheres and cells in monolayers. Scratch assays demonstrated accelerated keratinocyte migration in vitro when treated with microencapsulated cells. In excisional wounds on the dorsa of diabetic mice, microencapsulated RIN-m cells accelerated wound closure by postoperative day 7; a statistically significant increase over AtT-20ins-treated and control groups. Histological results indicated significantly greater epidermal thickness in both microencapsulated RIN-m and AtT-20ins-treated wounds. The results suggest that microencapsulation enables insulin-secreting cells to persist long enough at the wound site for a therapeutic effect and thereby functions as an effective delivery vehicle to accelerate wound healing.
Introduction

S
kin acts as a protective barrier against environmental toxins and provides thermoregulation and fluid homeostasis. 1 Any injury to the skin results in its loss of structural and functional integrity. Following injury, a wound healing cascade sets into play in three sequential phases that dynamically interact and overlap in time. The inflammatory response is the key to effective wound healing. Macrophages prepare the wound bed by clearing tissue debris, which allows new vessel formation and infiltration of fibroblasts and nutrients to begin healing. 2 Nonhealing wounds have a hyperglycemic wound environment that causes immune cells to produce proinflammatory cytokines and impairs phagocytosis.
If inflammation is not controlled and inflammatory cells persist in the wound site, it may lead to chronic inflammation. In chronic inflammation, activated neutrophils enter a selfsustaining cycle characterized by a continuous breakdown of wound matrix by oxidative enzymes such as matrix metalloproteases (MMPs). 3 In this environment, MMPs rapidly degrade extracellular matrix components deposited by fibroblasts. 4 The end result is decreased angiogenesis, reepithelialization, wound contraction, and reduced wound strength.
The use of insulin for wound healing applications dates back to the 1920s. One of the earliest studies by Rosenthal showed that rats treated with a topical insulin suspension demonstrated increased wound tensile strength. 5 Insulin has also been shown to promote closure of in vitro wound models by activating the ERK1/2 and PI3K signaling.
downstream target AKT. The PI3K/AKT pathway is activated in an insulin-dependent manner and is implicated in wound healing. Insulin also prevents apoptotic cell death induced by inflammatory stimuli by counteracting the dephosphorylation of AKT by TNF-a and promotes angiogenesis by stimulating expression of VEGF through AKT signaling. 7 Rabinowitch reported disturbed sugar metabolism in nondiabetic patients presenting with slow wound healing arrested in the inflammatory phase. 8, 9 Blood samples in these patients did not meet the diagnostic criteria for diabetes, but abnormal blood sugar time curves were observed. Their findings suggest that carbohydrate metabolism may be disturbed during wound healing and may actually be impairing wound repair when infection is present. Insulin regulates and induces the infiltration of macrophages, thereby promoting resistance to infection by eliminating pathogens and clearing cellular debris. 10 Insulin plays a vital role in several cellular processes and serves as a chemoattractant and mitogen for cells necessary for wound healing, promoting growth, proliferation, secretion, and migration of keratinocytes, endothelial cells, and fibroblasts, all of which are essential in wound healing.
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For instance, insulin is essential for glucose utilization by fibroblasts when they are producing collagen and its exogenous application increases collagen deposition 4 ; the proliferation and migration of endothelial cells are necessary for the formation of new blood vessels, both of which are promoted by insulin; and this insulin-mediated angiogenesis results in vessels that deliver the required nutrients and oxygen to the injured tissue, which thereby accelerates wound healing. Liu et al. demonstrated that insulin injection in mouse skin stimulated angiogenesis and led to longer and more branched blood vessels. 12 Chen et al. showed that insulin regulated the wound inflammatory response even in nondiabetic animals by inducing advanced infiltration and resolution of macrophages. 10 Lima et al. reported attenuation of insulin signaling pathways in the skin of diabetic animals and an increase in the time to complete wound closure; topically applied insulin cream improved wound healing rates in these animals. 13 Thus, exogenous insulin administration can be effective in accelerating wound healing in both diabetic and nondiabetic animals. [14] [15] [16] [17] [18] Diabetic foot ulcers constitute a devastating subset of chronic wounds affecting the diabetic population, with estimates as high as 25% of all diabetics developing a foot ulcer in their lifetime. 19, 20 These chronic ulcers have a propensity to infection and are one of the most common causes of amputations and morbidity in diabetic patients. Therapeutic approaches such as local debridement, skin grafts, dermal scaffolds, and growth factor treatments often yield less than satisfactory results due to the proinflammatory state of the wound. 21 Thus, there is a pressing need to develop therapies that can regulate the proinflammatory wound environment.
Insulin regulates the inflammatory state by regulating the hyperglycemic wound environment. 10 However, one barrier to widespread use of topical insulin therapies is the lack of a delivery system that maintains a steady dose and does not require repeated exposure of the wound. Other applications have successfully used cell therapies to achieve constant delivery of therapeutic products. Internal cell therapies have shown improved success when cells are enclosed in a barrier that protects them from the host immune response, thereby prolonging the viability and secretory characteristics of the cells. [22] [23] [24] Subcutaneous implantation of poly(ethylene glycol) diacrylate (PEGDA)-encapsulated human islets in type I diabetic patients has shown promising results of islet function with no evidence of autoimmune reaction. 23 PEGDA encapsulation has permitted successful transplantation of xenogeneic pancreatic islet cells: when porcine islets were implanted into diabetic rats, the animals achieved normoglycemia. 24 In fact, pancreatic islet cells encapsulated within PEGDA injected into diabetic humans and animals have successfully returned them to normoglycemia without the tissue typing required when these cells are not encapsulated. 22, 24 No external cell-based therapy involving insulin-secreting cells has yet been reported for treating chronic wounds. Herein, we describe a system that provides a sustained and steady dose of insulin to regulate the hyperglycemic wound environment characteristic of diabetic and chronic wounds. Through immunoisolation, the microencapsulation system preserves cell viability and the released bioactive insulin accelerates wound closure without the need for multiple applications.
Materials and Methods
Cell culture
The constant insulin-producing rat insulinoma beta cell line, RIN-m, and the glucose-stimulated insulin-releasing mouse sarcoma line, GLUT-2 cDNA-transfected AtT-20ins-(CGT6) cells, were purchased from American Type Culture Collection (ATCC, Manassas, VA) and propagated in RPMI-1640 medium (ATCC) or Dulbecco's modified Eagle's medium (DMEM; Sigma, St. Louis, MO), respectively, supplemented with 10% fetal bovine serum (FBS; Sigma) and 1% w/v penicillin-streptomycin (pen-strep; Sigma) in a humidified incubator at 37°C/5% CO 2 .
Microencapsulation
Cell-laden microspheres were formed as previously reported. 25, 26 Briefly, hydrogel precursor solution was formed by combining 0.1 g/mL 10 kDa PEGDA (10% w/v; Laysan Bio, Inc., Arab, AL) with (1.5% v/v) triethanolamine/HEPESbuffered saline (pH 7.4), 37 mM 1-vinyl-2-pyrrolidinone, 0.1 mM eosin-Y, and RIN-m cells or AtT-20ins cells for a final concentrationof1.5 · 10 4 cells/mL. A hydrophobic photoinitiator solution containing 2,2-dimethoxy-2-phenyl acetophenone in 1-vinyl-2-pyrrolidinone (300 mg/mL) was combined in mineral oil (3 mL/mL, embryo tested, sterile filtered; Sigma). The cellprepolymer suspension was added to the mineral oil solution, emulsified by vortexing for 4 s in ambient light, then for an additional 3 s under white light, then the vortex was stopped, and the emulsion was exposed to white light for 20 s with a vortex pulse at 10 s. Cross-linked microspheres were isolated by addition of 1 mL complete media, followed by centrifugation at 300 g for 5 min. The oil layer was removed by aspiration and pelleted microspheres were resuspended in media and placed in transwells (0.4 mm pore polycarbonate membrane Transwell inserts; Corning, Inc., Lowell, MA) in a 12-well plate with 3 mL culture medium. Microencapsulated cells were maintained in a humidified incubator at 37°C/5% CO 2 .
For glucose stimulation studies and cell migration studies, 3 · 10 6 insulin-secreting cells were encapsulated and 1 · 10 6 2724 AIJAZ ET AL.
insulin-secreting cells were plated on six-well tissue culture plates for comparisons. A higher count of cells was chosen for microencapsulation to account for the 37% microencapsulation efficiency of our procedure, which we initially determined while developing the microencapsulation protocol. Briefly, three 20 mL samples of microencapsulated cells from each group were placed in transwells in a 24-well plate with 1 mL of culture medium. Monolayer cells were trypsinized, counted with a hemocytometer, and a serial dilution was used as a standard curve. CellTiter 96 Ò AQueous One Solution Reagent (Promega Corporation, Madison, WI) at 200 mL was added into each well and the plate was incubated for 3 h in a humidified incubator at 37°C/5% CO 2 . The amount of soluble formazan produced by cellular reduction of the tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] was measured by reading the absorbance of the medium at 490 nm. Standard curves were used to calculate the number of live cells within microspheres, which in turn was used to determine the encapsulation efficiency. Since encapsulation efficiency was reproducibly 37%, 270% more cells were encapsulated when comparing against monolayer cells to equalize cell numbers between microencapsulated cell groups and monolayer groups.
Cell viability
Encapsulated cell viability was assessed on days 1, 3, 5, 7, 14, and 21 by incubating microsphere samples in media and 2 mM calcein acetoxymethyl ester and 4 mM ethidium homodimer (LIVE/DEAD Viability/Cytotoxicity Kit for mammalian cells; Life Technologies, Grand Island, NY) for 10 min at 37°C in a humidified 5% CO 2 incubator, then imaging the microencapsulated cells under an epifluorescent microscope (Zeiss Axiovert Observer Z1 Inverted PhaseContrast Fluorescent Microscope). Green fluorescent images for live cells and red fluorescent images for dead cells were separately processed on ImageJ software (Rasband, National Institutes of Health [NIH], Bethesda, MD) to obtain cell counts.
Static glucose stimulation
Cells in the monolayer or microspheres were maintained in complete culture medium at 37°C in a humidified 5% CO 2 incubator. After 48 h, microencapsulated cells and monolayer cells were washed twice with Krebs-Henseleit buffer (KHB; BIOTANG, Inc., Lexington, MA) containing 0.1% bovine serum albumin (Sigma) and preincubated in KHB without glucose for 60 min. Glucose was then added to the KHB to obtain glucose concentrations of 0.67, 1.67, 2.8 and 5.56 mM. Each concentration was used to perform static glucose incubations with each cell type for 2 h. At the end of the stimulation period, the incubation buffer was collected from each well and stored at -20°C until analysis. The insulin concentration of the samples was measured by the enzyme-linked immunosorbent assay (ELISA) kit (EMD Millipore, Billerica, MA).
Keratinocyte scratch assay
Human keratinocytes (HaCaT; Addex Bio, San Diego, CA) were propagated in DMEM (Sigma) supplemented with 10% FBS (Sigma) and pen-strep (Sigma) in a humidified incubator at 37°C/5% CO 2 . For scratch assays, 180,000 HaCaT cells/well were seeded onto 24-well plates (Greiner Bio-one, Monroe, NC). Cells were cultured for 48 h to form a confluent monolayer, at which time a single scratch of 175 -60 mm was produced in the center of the well with a 10-mL pipette tip. The wells were washed twice with Dulbecco's phosphate-buffered saline (Sigma) to remove cell debris. HaCaT cells were then stimulated with conditioned media from (1) empty microspheres (control); (2) microencapsulated RIN-m cells on days 1, 7, or 21; (3) microencapsulated AtT20ins cells on days 1, 7, or 21; (4) monolayer RIN-m cells on day 1; or (5) monolayer AtT-20ins cells on day 1. RIN-m and AtT-20ins cells were not maintained in monolayers beyond 4 days since the cells became overconfluent, resulting in cell death too great to collect insulin-conditioned media on days 7 and 21. HaCaT cell migration across the scratch was imaged at 0, 4, and 24 h using phase-contrast microscopy and analyzed on NIH ImageJ software.
Animal studies
A pilot animal study was performed to determine whether positive in vitro results could be translated to promising in vivo results. All procedures were performed in accordance with protocols approved by the Rutgers University Institutional Animal Care and Use Committee. Genetically diabetic male mice (BKS.Cg-Dock7 g +/+Lepr db /J; 10 weeks old, n = 9; Jackson Laboratories, Bar Harbor, ME) were anesthetized with isoflurane (Henry Schein, Melville, NY) adjusted as needed, vaporized in 1 L O 2 per minute, and kept on a heating pad at 37°C. Anesthesia was deemed sufficient when the animal lacked a contracting reflex in response to a toe pinch.
A standardized 1 · 1 cm template was used to mark their dorsa, and full-thickness wounds (epidermis, dermis, and underlying panniculus carnosus) were created by excising the marked dorsal skin. Microencapsulated RIN-m or AtT20ins cells or empty microspheres were applied to wounds, which were then covered with TegadermÔ and photographed at postoperative days (POD) 3, 7, 14, 21, 28, and 35 for gross appearance. Tegaderm began to fail on POD 16 and therefore all microspheres were then removed. Wound area was measured by tracing the wound margins using ImageJ. Wound closure was calculated as percent area of original wound. Animals were sacrificed by CO 2 inhalation on POD 35 and wound tissue was explanted for histology.
Histological analysis
Wound tissues were fixed in 10% formalin for 24 h at room temperature, and then stored in 70% ethanol at 4°C until serial sectioning (5 mm thick) and staining with hematoxylin and eosin (H & E) or Picric Acid Sirius Red (PASR) at the Digital Imaging and Histology Core, Rutgers NJMS Cancer Center. Histological images were analyzed on ImageJ software to find epidermal and dermal thickness and collagen density. H & E-stained sections were analyzed in ImageJ to measure the thickness of epidermis and dermis using the line selection tool. Lines were created across the thickness of the epidermal or dermal boundaries at five random locations in each H & E section and lengths were averaged. RGB images of PASR-stained sections were converted to grayscale by splitting the images into red, green, and blue channels. For accurate visual determination of image threshold for collagen-stained areas, the red channel was selected as it yielded the best contrast between the stain and the background. The thresholded images were analyzed to measure percent area of collagen density. 27 
Statistical analyses
All data were taken in triplicate and reported as mean -standard deviation. Viability, insulin release, scratch closure, dermal and epidermal thickness, collagen density, and wound closure were compared between the different treatment groups using one-way analysis of variance. Pairwise comparisons were made between groups using Fisher's least significant difference post hoc test. p-Values < 0.05 were considered significant. All analyses were performed using KaleidaGraph statistical software version 4.1.0, Synergy Software (Reading, PA).
Results
Effect of microencapsulation on cell viability
The cell viability/cytotoxicity assay demonstrated the effect of microencapsulation on cell viability. Live cells within microspheres were identified based on intracellular enzymatic conversion of nonfluorescent calcein-AM to green fluorescent calcein, while ethidium homodimer-1 penetrated damaged membranes of dead cells and, upon binding to nucleic acids, fluoresced bright red (Fig. 1) . Microencapsulated RIN-m cell viability was 66.5% -8.8% on day 1 and dropped to 80% of the initial encapsulated cell viability on day 7 (53.9% -3.7%), and then to 64% of the initial viability postencapsulation on day 21 (42.6% -7.7%) (Fig. 2) . Microencapsulated AtT-20ins cells demonstrated higher cell viability at 70.6% -8.23% on day 1, which dropped to 82.5% of the starting viability by day 7 (58.2% -17.9%) and 66% of the initial viability on day 21 (46.6% -9.9%).
Insulin release kinetics
Both monolayer and microencapsulated RIN-m cells did not respond to glucose stimulation and maintained a constant insulin secretion profile when exposed to incremental concentrations of glucose and on average secreted 0.48 -0.03 and 0.35 -0.16 ng/mL/h insulin, respectively (Fig. 3A) . AtT-20ins cells responded to glucose stimulation and demonstrated significant increases in insulin secretion at incremental glucose concentrations (Fig. 3B) . Maximum increases in insulin release were observed at 5.56 mM glucose: for the monolayer, 0.53 -0.05 ng/mL/h, and for encapsulated cells, 0.66 -0.12 ng/mL/h, which corresponded to insulin increases of 3.9 and 3.6-fold greater than control (0 mM glucose) for monolayer and encapsulated cells, respectively. No significant difference in insulin release was observed between microencapsulated and monolayer cells.
Insulin stimulated cell migration
Bioactivity of the insulin released from microencapsulated insulin-secreting cells was assessed by demonstrating their effect on keratinocyte migration. Keratinocytes were plated in a monolayer to simulate the epidermal layer of the skin and a defect (scratch assay) was created to simulate wound healing in vitro (Fig. 4) . Conditioned media containing insulin released from RIN-m microspheres sampled on day 1 demonstrated significantly increased rate of scratch closure compared with media from control empty microspheres ( p < 0.05) (Fig. 5A) . The concentration of insulin from sampled media is shown in Figure 6 . For RIN-m cells, monolayers had the highest concentration of insulin, while for AtT-20ins cells, day 21 microencapsulated cells had the highest insulin concentrations. The rate of scratch closure was 29.5 -8.7 and 6.9 -11.6 mm/h for insulin sampled on day 1 from RIN-m microspheres and media from empty microspheres, respectively. The rate of scratch closure for monolayer scratches stimulated with insulin from day 1 monolayer RIN-m cells was 22.9 -8.4 mm/h, which was less than the closure observed in the microencapsulated group, but not significantly so. No significant difference in rate of scratch closures was observed for keratinocyte monolayers treated with insulin-conditioned media sampled from RIN-m microspheres on days 1, 7, or 21.
Similar results were observed for keratinocyte scratches treated with insulin-conditioned media from AtT-20ins microspheres. A significantly greater rate of scratch closure was observed in scratches stimulated with insulin released from day 1 AtT-20ins microspheres (19.8 -11.7 mm/h) compared with scratches treated with insulin released from AtT-20ins monolayer cells (18.6 -9.5 mm/h) or negative control empty microspheres (6.9 -11.6 mm/h) (Fig. 5B) . Insulin-conditioned media sampled on day 7 from AtT20ins microspheres also showed a significant rate of scratch closure (19.2 -11.1 mm/h) compared with control empty microspheres (6.9 -11.6 mm/h). The rate of closure in scratches treated with insulin sampled on day 21 from AtT20ins microspheres was not significantly different from the rate of closure in scratch wounds treated with media from empty microspheres.
Empty microspheres served as insulin-free negative controls and failed to demonstrate any stimulation of cell migration across the scratches.
In vivo assessment of wound closure in diabetic mice
Gross examination showed an initial increase in wound area due to skin elasticity of the obese diabetic mice. Animals treated with RIN-m microspheres showed statistically significant acceleration in wound closure by POD 7 (5.07% -19.5%) compared with AtT-20ins and control groups (Fig.  7B) . By POD 21 wound closures for RIN-m, AtT-20ins, and control groups were 84.3% -13.62%, 57.4% -36.2%, and 72.98% -7.01%, respectively. Complete wound closure was achieved by POD 28 in all animals (n = 3) treated with RIN-m microspheres, while wound closures were 89.3% -15.33% and 94.39% -2.06% in AtT-20ins-treated animals (n = 3) and negative control animals (n = 3), respectively. Large standard deviations in wound closures were observed in AtT-20ins-treated animals. In this group, complete wound closure was achieved in two animals by POD 35, while in the third animal, wound closure was 82%.
Histological analysis
After sacrifice on POD 35, skin tissue was excised around the edges of the wounded area for histological analysis. Tissue sections were stained with H & E for morphological analysis and PASR stain for collagen fiber density (Fig. 8) . Microencapsulated insulin-secreting cells accelerated wound closure and H & E sections showed that the epidermis was three to five cells thick in both treatment groups, while it was only one to two cells thick in the empty microsphere control group. Quantification of H & E sections revealed that the epidermis was significantly thicker in animals treated with RIN-m microspheres (42.7 -10.37 mm) and AtT-20ins microspheres (44.15 -10.26 mm) compared with the negative control animals (29.98 -7.96 mm) (Fig. 8G) . No statistically significant difference was observed in dermal thickness between the treatment and control groups (Fig. 8H) ; however, when the density of collagen fibers was analyzed in the PASR-stained sections, collagen fiber density (percent area) was significantly higher in RIN-m (83.74% -2.7%) and AtT- 20ins (79.95% -3.7%) treatment groups compared with the control group (67.35% -2.74%) (Fig. 8I ).
Discussion
Wound healing is a dynamic process that occurs in a wellorchestrated synchrony of events that overlap and are interdependent. Any biological or temporal defect may affect wound healing. Tight regulation and resolution of the inflammatory response, as well as initiation of reepithelialization, are critical to effective wound healing. Previous studies have reported that topical application of insulin accelerates wound healing by regulating the hyperglycemic wound environment and by promoting growth and proliferation of keratinocytes, fibroblasts, and endothelial cells in both diabetic and nondiabetic patients. However, current approaches require repeated applications that increase the chances of infecting the wound with each opening of the wound dressing for every application. Cells that secret insulin into the wound area provide a solution to this problem. In this study, we presented a novel system that encapsulates constant or glucose-dependent insulin-secreting cells within synthetic hydrogels formed from PEGDA. This approach maintains cell viability and insulin secretory characteristics of the cells while at the same providing a bioinert nonimmunogenic barrier. Moreover, insulin secretion is modulated in a sustained manner, eliminating the need for multiple applications as required in topical insulin ointments.
Cell viability and cytotoxicity assays showed that the majority of cells survived the microencapsulation process. Data showed a gradual decline in viability over 21 days, which is expected since cells do not proliferate in these hydrogels. The total number of insulin-releasing cells is more significant than the percentage of live cells, as demonstrated by the bioactivity and wound healing studies. Glucose stimulation studies demonstrated that the encapsulated cells maintained their insulin secretory characteristics and the microspheres' hydrogel mesh permitted free diffusion of insulin through the microspheres. The insulin molecule has a molecular weight of 5808 Da and a molecular radius of 1.34 nm. 28 Free diffusion of insulin from microspheres as confirmed by our data was as expected since the mesh size of the 10% 10 kDa PEGDA that we used has a mesh size of 28 nm. 29 Thus, no statistically significant difference in insulin secretion was observed between monolayer insulin-secreting cells and microencapsulated insulin-secreting cells.
Once the release of insulin from the microspheres was confirmed, it was also important to determine whether the released insulin remained bioactive, which was accomplished by demonstrating that the released insulin was capable of stimulating a wound healing response. The keratinocyte scratch assay is an in vitro wound healing model and stimulation of HaCaT cell migration by insulin is an accepted (Fig. 6) , which is comparable with the typical 10 -7 M concentration of insulin used to stimulate keratinocyte migration. 30, 31 The bioactivity of insulin released from microspheres was maintained over time as indicated by its continued ability to accelerate scratch closure.
Specifically, cell migration studies demonstrated that the insulin released from microencapsulated RIN-m cells remained bioactive for at least 21 days, which is sufficient time for a wound to completely heal. The rate of closure observed in scratches treated with insulin released from days 1, 7, and 21 RIN-m microspheres was not significantly different between groups, but each group was significantly greater than the (control) empty microsphere group ( p < 0.05). Decreases in the rate of scratch closure were observed in scratches treated with insulin collected on day 21 from microencapsulated AtT-20ins cells compared with scratches treated with insulin collected on day 1. This reduction in the rate of scratch closure could be due to loss of microspheres during media collection or loss of cell viability over time and therefore reduced concentration of insulin in the sample used to stimulate HaCaT cell migration. Further experiments will be conducted to elucidate these results.
In nondiabetic mice, the relatively large 1 cm 2 fullthickness excisional wound has been shown to take 25 days to heal. 32 In the diabetic mice in this study, the untreated wound takes over 35 days to heal, 40% longer. Thus, although the wounds show 94% closure, this closure is well past the normal time it should have taken. The percentage wound closure calculated for each group demonstrated a trend of accelerated closure in insulin-treated animals before removal of microspheres on POD 16, after which negative control (empty microspheres) animals showed similar wound closure dynamics. Insulin is typically applied at 0.03 U in 20 mL saline to treat excisional wounds in mice, which is equivalent to 52.05 ng/mL, while our study reports accelerated wound healing at much lower concentration. 9, 30 Histology showed no evidence of immune reaction to empty PEGDA hydrogel microspheres or those containing insulin-secreting cells. The large standard deviation in percentage wound closure for microencapsulated AtT-20ins cells might be attributed to the fact that these cells grow in clusters, which may result in varying cell densities within . Quantification of (G) epidermal thickness, (H) dermal thickness, and (I) collagen fiber density. Although there is no statistical difference in dermal thickness between groups, epidermal thickness in treated wounds is statistically greater than control. Collagen fiber densities in treated groups are also statistically greater than control. Asterisks indicate statistically significant differences ( p < 0.05) between treated and control wounds. Error bars show standard error of mean. Scale bars = 50 mm. Color images available online at www.liebertpub.com/tea microspheres between animals. This is due to the fact that our microencapsulation method is not 100% efficient and more reproducibly encapsulates individual cells than clusters. In future, this could be rectified by encapsulating cells in thin sheets using molds and a method that does have 100% encapsulation efficiency; however, based on our results, we will proceed with RIN-m cells, which demonstrated superior wound healing and do not grow in clusters. The healing attained with RIN-m cells suggests that the presence of insulin is sufficient for wound healing and does not need to be tailored to the glucose environment of the wound bed.
Conclusions
In this study, a system for accelerated wound healing, in which insulin-secreting cells encapsulated into PEGDA hydrogel microspheres, was evaluated. This permitted prolonged insulin release within the target site. Microsphere encapsulation prevented immune clearance and migration, keeping the microencapsulated cells in the desired location. Thus, the combination of insulin-releasing cells and PEGDA hydrogel microencapsulation provides a novel method for delivering a steady constant dose of insulin to a wound. Future studies will explore dose responses, various hydrogel geometries, and insulin-mediated induction of downstream signaling molecules. Our system is the first cell-based insulin treatment of its kind to speed wound closure, demonstrating that this system is a feasible method to accelerate wound healing and it may impact insulin-driven wound healing approaches to come.
